About

- About Circio
- CEO Statement
- Pipeline
- Management Team
- Board of Directors
- Careers
- The Norwegian Transparency Act

circRNA

- Circio AB
- circVec platform

Clinical programs

- KRAS program
- Publications

Partnering

Investors

- Reports
- Presentations
- Prospectus
- Debt

Media

- Press releases
- Events
- Subscribe
- Contact

Contacts

About
circRNA
- Circio AB
- circVec platform
Clinical programs
- KRAS program
- Publications
Partnering
- Partnering
Investors
Media
Contacts
- Offices
- Investors & Media

Search for:

Extraordinary General Meeting November 2017

November 30, 2017

01:00 PM CET
Oslo, Norway

Documents

Notice of EGM
Protocol

IR contact

Dr Erik Digman Wiklund

CEO

erik.wiklund@circio.com

(+47) 41 33 35 36

Dr Lubor Gaal

CFO & Head of BD

lubor.gaal@circio.com

(+34) 683 343 811

Annual and ESG Report for 2023

Circio released the Annual Report for 2023 on Thursday 25 April 2024

2023 CRNA Annual Report
Circio presentation April 2024
2023 ESG report
Webcast: circVec data update and 2023 annual accounts

Read the report

Subscribe

Press releases

Financial reports

Language

English

Norwegian

Read more about our Protection of your personal data.

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

About
circRNA
Clinical programs
Partnering
Investors
Media
Contacts

CONTACT

Circio Holding ASA
Email: contact@circio.com

Cookies
Privacy policy

STAY CONNECTED